Fredun Pharmaceuticals has released its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a total income from operations of 482.43 Cr.

Net profit for the quarter stood at 36.03 Cr, with Earnings Per Share (EPS) reaching 83.3. These results, approved by the Board, offer key insights into the company's recent performance for investors.